340 results on '"Tollefson G"'
Search Results
2. VIVA (VIsualization of VAriants): A VCF File Visualization Tool
3. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders
4. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
5. A Canadian customer survey to assess power system reliability worth
6. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression
7. Introduction
8. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses
9. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double‐blind controlled trial
10. P.1.035 Onset of improvement in emotional and painful physical symptoms of depression with duloxetine treatment
11. Predictors of antipsychotic treatment response in patients with first episode schizophrenia, schizoaffective, and schizophreniform disorders
12. Olanzapine-fluoxetine combination in treatment-resistant depression
13. Olanzapine-fluoxetine combination for treatment of psychotic depression
14. Industrial and university test research collaboration
15. The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease
16. A double blind study of olanzapine-fluoxetine combination for treatment of psychotic major depression
17. IS OLANZAPINE A MULTI-ACTING RECEPTOR TARGETED ANTIPSYCHOTIC (MARTA)?
18. Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms
19. Anxious?depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?
20. Olanzapine versus haloperidoi treatment in first-episode psychosis
21. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: Results from a randomized clinical trial
22. Olanzapine versus placebo in rapid-cycling bipolar disorder
23. Suicidal risk in patients treated with the novel antipsychotic olanzapine
24. Sex and neuroendocrine differences in response to treatment with olanzapine: A preliminary analysis
25. Long-term treatment in panic disorder: Randomization of acute fluoxetine responders to continued treatment with fluoxetine or placebo
26. Olanzapine versus risperidone in the treatment of schizophrenia and related psychotic disorders
27. Olanzapine in the treatment of schizoaffective disorder
28. Fluoxetine treatment of panic disorder: A randomized, placebo-controlled, multi-center trial
29. Olanzapine versus risperidone and haloperidol in treatment of schizophrenia
30. Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease
31. Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy
32. Olanzapine in the treatment of schizoaffective disorder
33. Acute and long-term results of the dose ranging double-blind olanzapine trial
34. Olanzaplne versus placebo, results of the United-States double-blind olanzapine trial
35. Acute and long-term results of the North American double-blind olanzapine trial
36. Comparison of extrapyramidal syndromes between olanzapine and placebo in schizophrenia
37. Olanzapine versus haloperidol: acute results of the multi-center international trial
38. Long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol
39. Olanzapine versus haloperidol: Long-term results of the multi-center international trial
40. Is there a relationship between baseline and treatment-associated changes in [H]-IMI platelet binding and clinical response in major depression?
41. Additional clinical experience with olanzapine, an “atypical” antipsychotic
42. Olanzapine, a new “atypical” antipsychotic
43. Consulting end-users on infrastructure worth
44. How long to onset of antidepressant action
45. Assessment of electric service reliability worth
46. Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression
47. Comorbid anxious signs and symptoms in major depression
48. Pharmacotherapy of obsessive compulsive disorder-experience with fluoxetine
49. A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholia
50. DOES ANXIETY OR INSOMNIA, AS PART OF MAJOR DEPRESSION, PREDICT A DIFFERENTIAL RESPONSE TO THE TYPE OF ANTIDEPRESSANT PRESCRIBED?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.